NONOF Stock - Novo Nordisk A/S
Unlock GoAI Insights for NONOF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $290.40B | $232.26B | $176.95B | $140.80B | $126.95B |
| Gross Profit | $245.88B | $196.50B | $148.51B | $117.14B | $106.01B |
| Gross Margin | 84.7% | 84.6% | 83.9% | 83.2% | 83.5% |
| Operating Income | $128.34B | $102.57B | $74.81B | $58.64B | $54.13B |
| Net Income | $100.99B | $83.68B | $55.52B | $47.76B | $42.14B |
| Net Margin | 34.8% | 36.0% | 31.4% | 33.9% | 33.2% |
| EPS | $22.68 | $9.34 | $12.26 | $10.40 | $9.03 |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit WebsiteEarnings History & Surprises
NONOFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | — | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.77 | $0.71 | -7.9% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $0.94 | $0.94 | +0.5% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.89 | $0.96 | +8.6% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $0.83 | $0.88 | +5.9% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.90 | $0.92 | +2.5% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.70 | $0.65 | -7.0% | ✗ MISS |
Q2 2024 | May 2, 2024 | $0.75 | $0.82 | +8.2% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $0.68 | $0.72 | +6.8% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $0.68 | $0.71 | +4.0% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $0.67 | $0.63 | -5.8% | ✗ MISS |
Q2 2023 | Jun 26, 2023 | $0.61 | $0.64 | +4.2% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $0.84 | $0.88 | +3.8% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.82 | $0.84 | +2.2% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.82 | $0.80 | -2.2% | ✗ MISS |
Q2 2022 | Apr 29, 2022 | $0.81 | $0.88 | +9.0% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $0.72 | $0.73 | +1.3% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.78 | $0.82 | +5.4% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.76 | $0.83 | +10.2% | ✓ BEAT |
Latest News
Frequently Asked Questions about NONOF
What is NONOF's current stock price?
What is the analyst price target for NONOF?
What sector is Novo Nordisk A/S in?
What is NONOF's market cap?
Does NONOF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NONOF for comparison